A Multi-center, Prospective, Non-interventional (ni) Study Of The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-differentiated Unresectable Pancreatic Neuroendocrine Tumors
Phase of Trial: Phase IV
Latest Information Update: 19 Jan 2018
At a glance
- Drugs Sunitinib (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions
- Sponsors Pfizer
- 12 Jan 2018 Planned End Date changed from 1 Dec 2022 to 12 Dec 2022.
- 12 Jan 2018 Planned primary completion date changed from 1 Dec 2022 to 12 Dec 2022.
- 12 Dec 2017 Planned End Date changed from 1 Nov 2022 to 1 Dec 2022.